Isifo sesibindi esinamafutha e-Nonalcoholic (NAFLD) yimbangela eqhelekileyo yesifo esingapheliyo sesibindi emhlabeni jikelele. Ukuxilongwa okuqhelekileyo kubandakanya umfanekiso okanye ubungqina be-histological be-steatosis (amafutha esibindi aqokelelweyo) kwi-5% ye-hepatocytes, kunye nokungabikho kwezizathu ezaziwayo zesifo esingapheliyo sesibindi, njengokusetyenziswa kakubi kotywala, i-hepatitis yentsholongwane, izifo zesibindi, okanye ukusetyenziswa kwexesha elide le-steatogenic. amayeza. Ukwanda okumangalisayo kokuxhaphaka kwe-NAFLD kwiminyaka yamuva kunye neenkcazo zayo ezahlukeneyo zeklinikhi zifuna ukucaciswa kwesifo esicacileyo kunye neendlela zokuxilonga.
Iqela leengcali zamazwe ngamazwe kwi-pathology ye-hepatic isanda kufika kwisivumelwano sokuchaza kwakhona i-NAFLD kwi-metabolic (dysfunction) -enxulumene nesifo sesibindi esinamafutha (MAFLD). Le ngcamango isanda kucetywayo ibandakanya ubungqina be-hepatic steatosis kunye nokuba nokukhuluphala, uhlobo lwe-2 yeswekile mellitus (T2DM), okanye i-metabolic dysregulation. Kwinqaku lophononongo elapapashwa okokuqala kwi-intanethi nge-14 kaDisemba 2020 kwiJenali yezoNyango yaseTshayina, uProf. Fen Xu weSibhedlele seSithathu esiManyano neSibhedlele seYunivesithi yaseSun Yat-Sen, eTshayina, kunye noogxa bakhe baphonononga ukufana kunye nokungafani kwe-NAFLD kunye ne-MAFLD, ngokugxininisa ngakumbi. kwi-epidemiology, i-pathophysiology, ukuxilongwa, kunye ne-pharmacotherapy. "Le nkcazo entsha igxininisa ukubaluleka kokungasebenzi kakuhle kwe-metabolic kwisifo sesibindi esinamafutha," utshilo uProf. Xu.
Ngokucacileyo, ikota yabemi behlabathi iyahlangabezana nemigaqo yokuxilongwa kwe-NAFLD, abo bane-T2DM okanye ukutyeba kakhulu kunokuba nokwenzeka okuphezulu. Ngenxa yokuba i-MAFLD ibeka ugxininiso olongezelelweyo kwi-metabolism yokungasebenzi kwaye ibandakanya ukusela utywala, abaphandi bacinga ukuba inkcazo entsha iya kukhokelela ekwandiseni uqikelelo lokuxhaphaka. Ngapha koko, ukwanda kokuxhaphaka kokutyeba kakhulu kunye ne-T2DM kuya kukhokelela ekunyukeni ngokukhawuleza kwe-MAFLD. Inkcazo entsha iya kunceda uphando lwexesha elizayo ngokuhlukanisa iimpawu ze-epidemiological kunye neendlela ezahlula i-MAFLD kwi-NAFLD.
Ukufunyaniswa kwangethuba kwe-MAFLD kuya kuthi, ngokunjalo, kukhuthaze ukuqaliswa kwangethuba kwamanyathelo okunciphisa iimpembelelo zempilo. Ngaphezu koko, ulungelelwaniso phakathi kwe-T2DM, ukukhuluphala, kunye ne-MAFLD ibonisa ukuba i-anti-obesity kunye ne-anti-hyperglycemic drugs inokusebenza ekuphuculeni i-histology yesibindi kunye neziphumo zekliniki kwizigulane ezine-MAFLD. Kwakhona, iziyobisi ezisebenzayo ekukhuseleni isifo senhliziyo kwizigulane ezine-T2DM zinokunciphisa umngcipheko wokufa kwentliziyo kwizigulane ezine-MAFLD. Nangona kunjalo, iimvavanyo zeklinikhi ziya kuba yimfuneko ukuqinisekisa ukuba uncedo lwamachiza anjalo kwizigulane ezine-MAFLD.
Ukutshintshwa kokuhlelwa ukusuka kwi-NAFLD ukuya kwi-MAFLD kuya kuba nemiphumo ebalulekileyo, kubandakanywa nobudlelwane obuthe ngqo kunye nokuvunywa ngokucacileyo kunye nezinye izifo ezifana nokukhuluphala kunye ne-T2DM. "Kukho imfuneko enyanzelekileyo yokucacisa iimpawu ze-epidemiological kunye neendlela eziqhuba uphuhliso kunye nokuqhubela phambili kwe-MAFLD. Oku kunokunceda kakhulu ekuphunyezweni kweenkqubo zokuxilongwa kwangethuba kunye nonyango,” uqukumbela ngelitshoyo uProf. Xu.
INTO ONOKUYITHATHA KWELI NQAKU:
- Conventional diagnosis includes imaging or histological evidence of steatosis (accumulated liver fat) in >5% of hepatocytes, and the absence of known causes of chronic liver disease, like alcohol abuse, viral hepatitis, hereditary liver diseases, or long-term usage of steatogenic medications.
- Fen Xu of The Third Affiliated Hospital of Sun Yat-Sen University, China, and his colleagues explore the similarities and differences of NAFLD and MAFLD, with particular emphasis on epidemiology, pathophysiology, diagnosis, and pharmacotherapy.
- A group of international experts in hepatic pathology has recently arrived at a consensus to redefine NAFLD to metabolic (dysfunction)-associated fatty liver disease (MAFLD).
